- Brian Piwek to Assist in Generating New Retail Licensing Opportunities
LAS VEGAS, Feb. 1 /CNW/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI)
(http://www.skinvisible.com), a pharmaceutical company focused on the
discovery and development of patented dermatology products with their
proprietary polymer delivery system Invisicare(R), today announced that Mr.
Brian Piwek has been selected as a new member of the Company's Board of
Directors replacing Mr. Jost Steinbruchel, who has resigned as a Board Member.
Mr. Steinbruchel has been a Board Member since the company's inception in 1998
and the board and company officers wish to thank him for his valuable
contribution during this time.
"We are delighted to have Mr. Brian Piwek join our Board of Directors, as
he brings a great deal of experience and additional perspective that will be
an asset to Skinvisible as we continue to implement our current initiatives,"
said Mr. Terry Howlett, President / CEO of Skinvisible. "We are entering an
exciting phase at Skinvisible where we begin the commercialization of our
dermatology products with international licensees. Brian's business
development and retail expertise will be invaluable as Skinvisible continues
to pursue its growth goals."
Brian Piwek's experience and expertise is in the international retail
industry. He was president of Overwaitea Foods supermarket from 1991 until
1997. In 1997 Brian accepted the position as Co-CEO with A&P Canada (The Great
Atlantic & Pacific Tea Company Inc.) and in 2000 was appointed Chairman,
President and CEO of A&P Canada. In late 2002 he moved to the U.S. as
President and Chief Executive Officer of A&P US (New York Stock Exchange
symbol "GAP") where he began the turnaround of North America's oldest retail
food chain. Brian retired from A&P in July 2005. Brian has been recognized
for his achievements throughout his career including "President of the Year"
by the Jim Pattison Group for the outstanding financial performance of
Overwaitea in 1993. Brian is an MBA graduate and has served on many voluntary
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible
Inc., is a research-and-development company whose primary business objective
is to license its proprietary formulations with Invisicare to pharmaceutical
and cosmeceutical companies as well as assisting companies in revitalizing or
enhancing their existing skin care products. Skinvisible receives a
combination of research and development fees, upfront license fees, and
ongoing royalties for the life of the patent. http://www.skinvisible.com
Invisicare is a patented polymer delivery system developed to hold active
ingredients topically on the skin for extended periods of time. A key benefit
is that Invisicare is non-occlusive on the skin, allowing normal skin
respiration and perspiration. The Company has developed a portfolio of topical
products using Invisicare for the dermatology and cosmeceutical industries.
This press release contains 'forward looking' statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks and
uncertainties associated with an emerging company. Actual results could differ
materially from those projected in the forward looking statements as a result
of risk factors discussed in Skinvisible, Inc. reports on file with the U.S.
Securities and Exchange Commission (including, but not limited to, a report on
Form 10Q for the quarter ending December 31, 2007).
Terry Howlett, President/CEO
Skinvisible Pharmaceuticals, Inc
For further information:
For further information: Terry Howlett, President|CEO of Skinvisible,
Inc., +1-702-433-7154, firstname.lastname@example.org Web Site: